Insider filing · ARDX

David M Mott bought $993K of Ardelyx (ARDX)

Executed Jan 21 2025, disclosed Jan 22 2025, 1 day later.

Over the 21 trading sessions from the disclosed entry session (Jan 22 2025), the stock returned +16.7% (delay-adjusted); from the execution session (Jan 21 2025), +25.9%. Derived: entry at the session's open, exit at the close 20 sessions later.

DM David M Mott Director profile →

David M Mott (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Ardelyx, Inc. (ARDX). Across 1 priced purchase filing, the average 21-session return was -18.2% from execution and -6.2% from disclosure (delay-adjusted; derived). The largest single filing was $1.9M of ARDX (333,333 sh × $5.84, as filed), executed Feb 20.

ARDX Ardelyx, Inc. ARDX · Healthcare · 36 filings in 24 months ticker →

Healthcare · Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→